Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983329 | 1.00 | CASP3 (0.46) | CASP3TLR2PTPN1 | |
| SCHEMBL26923683 | 0.86 | CASP3 (0.54) | CASP3TLR2PTPN1 | |
| SCHEMBL31550501 | 0.83 | TLR2 (0.42) | CASP3TLR2PTPN1 | |
| SCHEMBL25294095 | 0.82 | CASP3 (0.49) | CASP3TLR2PTPN1 | |
| SCHEMBL30715246 | 0.82 | CASP3 (0.55) | CASP3TLR2PTPN1 | |
| SCHEMBL30715198 | 0.81 | CASP3 (0.49) | CASP3TLR2PTPN1 | |
| SCHEMBL31559011 | 0.80 | CASP3 (0.58) | CASP3PTPN1 | |
| SCHEMBL31217797 | 0.79 | CASP3 (0.46) | CASP3TLR2PTPN1 | |
| SCHEMBL30715210 | 0.78 | CASP3 (0.47) | CASP3PTPN1 | |
| SCHEMBL31065851 | 0.78 | CASP3 (0.46) | CASP3TLR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325688-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | MEDILINK THERAPEUTICS SUZHOU CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-119212733-A | Antibody drug conjugate containing protein degradation agent bioactive compound, and preparation method and application thereof | 苏州宜联生物医药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024153185-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING BCL-2 FAMILY PROTEOLYSIS AGENT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325688-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | PSMA6, PSMA1, PSMA8 | CASP3 740/4885TLR2 4088/4885PTPN1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.